Literature DB >> 23660218

MicroRNAs as potential therapeutic targets in kidney disease.

Ivan G Gomez1, Monica Grafals, Didier Portilla, Jeremy S Duffield.   

Abstract

One cornerstone of chronic kidney disease (CKD) is fibrosis, as kidneys are susceptible due to their high vascularity and predisposition to ischemia. Presently, only therapies targeting the angiotensin receptor are used in clinical practice to retard the progression of CKD. Thus, there is a pressing need for new therapies designed to treat the damaged kidney. Several independent laboratories have identified a number of microRNAs that are dysregulated in human and animal models of CKD. This review will explore the evidence suggesting that by blocking the activity of such dysregulated microRNAs, new therapeutics could be developed to treat the progression of CKD.
Copyright © 2013. Published by Elsevier B.V.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23660218      PMCID： PMC4017353          DOI： 10.1016/j.jfma.2012.12.011

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN： 0929-6646            Impact factor:   3.282


  39 in total

Review 1.  Subtle acquired renal injury as a mechanism of salt-sensitive hypertension.

Authors:  Richard J Johnson; Jaime Herrera-Acosta; George F Schreiner; Bernardo Rodriguez-Iturbe
Journal:  N Engl J Med       Date:  2002-03-21       Impact factor: 91.245

Review 2.  MicroRNA regulation of gene expression in plants.

Authors:  Diana V Dugas; Bonnie Bartel
Journal:  Curr Opin Plant Biol       Date:  2004-10       Impact factor: 7.834

3.  A short history of a short RNA.

Authors:  Rosalind Lee; Rhonda Feinbaum; Victor Ambros
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

4.  Injury and progressive loss of peritubular capillaries in the development of chronic allograft nephropathy.

Authors:  Yasuo Ishii; Tokihiko Sawada; Keiichi Kubota; Syouhei Fuchinoue; Satoshi Teraoka; Akira Shimizu
Journal:  Kidney Int       Date:  2005-01       Impact factor: 10.612

5.  PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis.

Authors:  Heather A Burgess; Louis Eugene Daugherty; Thomas H Thatcher; Heather F Lakatos; Denise M Ray; Michelle Redonnet; Richard P Phipps; Patricia J Sime
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-02-25       Impact factor: 5.464

6.  Age-dependent hypertension in Mpv17-deficient mice, a transgenic model of glomerulosclerosis and inner ear disease.

Authors:  M Clozel; P Hess; W Fischli; B M Löffler; R M Zwacka; A Reuter; H Weiher
Journal:  Exp Gerontol       Date:  1999-12       Impact factor: 4.032

Review 7.  Nitric oxide, oxidative stress, and progression of chronic renal failure.

Authors:  Paul S Modlinger; Christopher S Wilcox; Shakil Aslam
Journal:  Semin Nephrol       Date:  2004-07       Impact factor: 5.299

8.  Transgenic expression of proximal tubule peroxisome proliferator-activated receptor-alpha in mice confers protection during acute kidney injury.

Authors:  Shenyang Li; Kiran K Nagothu; Varsha Desai; Taewon Lee; William Branham; Carrie Moland; Judit K Megyesi; Mark D Crew; Didier Portilla
Journal:  Kidney Int       Date:  2009-08-26       Impact factor: 10.612

9.  PPAR-alpha ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G.

Authors:  Shenyang Li; A Basnakian; Renu Bhatt; Judit Megyesi; Neriman Gokden; Sudhir V Shah; Didier Portilla
Journal:  Am J Physiol Renal Physiol       Date:  2004-07-27

10.  Functional rescue of the glomerulosclerosis phenotype in Mpv17 mice by transgenesis with the human Mpv17 homologue.

Authors:  J Schenkel; R M Zwacka; C Rutenberg; A Reuter; R Waldherr; H Weiher
Journal:  Kidney Int       Date:  1995-07       Impact factor: 10.612
View more
  6 in total

1.  Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways.

Authors:  Ivan G Gomez; Deidre A MacKenna; Bryce G Johnson; Vivek Kaimal; Allie M Roach; Shuyu Ren; Naoki Nakagawa; Cuiyan Xin; Rick Newitt; Shweta Pandya; Tai-He Xia; Xueqing Liu; Dorin-Bogdan Borza; Monica Grafals; Stuart J Shankland; Jonathan Himmelfarb; Didier Portilla; Shiguang Liu; B Nelson Chau; Jeremy S Duffield
Journal:  J Clin Invest       Date:  2014-11-21       Impact factor: 14.808

2.  Acute pyelonephritis in renal allografts: a new role for microRNAs?

Authors:  Steve Oghumu; Anna Bracewell; Uday Nori; Kirsteen H Maclean; Joan-Miquel Balada-Lasat; Sergey Brodsky; Ronald Pelletier; Mitchell Henry; Abhay R Satoskar; Tibor Nadasdy; Anjali A Satoskar
Journal:  Transplantation       Date:  2014-03-15       Impact factor: 4.939

Review 3.  The proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction.

Authors:  Robert L Chevalier
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-18

Review 4.  Activators of SIRT1 in the kidney and protective effects of SIRT1 during acute kidney injury (AKI) (effect of SIRT1 activators on acute kidney injury).

Authors:  Alireza Raji-Amirhasani; Mohammad Khaksari; Fatemeh Darvishzadeh Mahani; Zahra Hajializadeh
Journal:  Clin Exp Nephrol       Date:  2021-03-29       Impact factor: 2.801

5.  Dicer1 activity in the stromal compartment regulates nephron differentiation and vascular patterning during mammalian kidney organogenesis.

Authors:  Naoki Nakagawa; Cuiyan Xin; Allie M Roach; Natalie Naiman; Stuart J Shankland; Giovanni Ligresti; Shuyu Ren; Suzanne Szak; Ivan G Gomez; Jeremy S Duffield
Journal:  Kidney Int       Date:  2015-02-04       Impact factor: 10.612

Review 6.  Loss of Mitochondrial Control Impacts Renal Health.

Authors:  Swayam Prakash Srivastava; Keizo Kanasaki; Julie E Goodwin
Journal:  Front Pharmacol       Date:  2020-12-09       Impact factor: 5.810
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.